← 프로그램 목록
ADCPhase 1Discontinued

Panobinostat

OHSU Knight Cancer Institute

비교

Panobinostat(OHSU Knight Cancer Institute)은 FRα 표적 ADC로, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: inhibits MYC expression, thereby suppressing the transcriptional activation of key components in the homologous recombination (HR) DNA repair pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 16.7% (ClinicalTrials.gov NCT01460940). 차별점: novel therapeutics could improve outcomes.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 12일 (2일 전)PK/독성 2026년 7월 12일 (2일 전)

FRα

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8

Discontinued

Technology

구조모아 · Maytansinoid/DM1

NK cells

DM4-6 inhibitors (KDMi), ML324, GSK-J4, and

novel therapeutics could improve outcomes

Mechanism of Action

inhibits MYC expression, thereby suppressing the transcriptional activation of key components in the homologous recombination (HR) DNA repair pathway

cytokine release and presentation of damage-associated molecular patterns

apoptosis

biomarkers due to its occult location and poor outcomes

Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 55건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2 · Phase 1, Phase 2 · Phase 1
  • Status: Completed · Unknown status · Terminated
  • 주요 endpoint: Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. · Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. · Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone · Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. · Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.
  • 등록된 결과: ORR 16.7%
  • 핵심: This phase II trial studies how well giving panobinostat together with lenalidomide works in treating patients with rela…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Panobinostat은 어떤 치료제인가요?
Panobinostat(OHSU Knight Cancer Institute)은 FRα 표적 ADC로, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Panobinostat의 임상 단계는?
Panobinostat의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.